AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10832622 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation in pure mitral stenosis
Number of subjects: 44
Study 10832622 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic evaluation in normal persons
Number of subjects: 44
Study 9094063 — intervention group
Group type: EXPERIMENTAL
Intervention: MMEPs recorded at 1, 3, 30, and 90 days after stroke, measuring amplitudes and latencies/central motor conduction times (CMCTs) from hypothenar, biceps brachialis, gastrocnemius, and quadriceps.
Number of subjects: 50
Study 9094063 — intervention group
Group type: EXPERIMENTAL
Intervention: MMEPs values included in prognosis calculations.
Number of subjects: 50
Study 9094063 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased blood pressure.
Number of subjects: 50
Study 9094063 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased heart rate and hyperglycemia.
Number of subjects: 50
Study 9094063 — intervention group
Group type: EXPERIMENTAL
Intervention: Variables: infarction size on second CT, age, and first day CMCT-S1.
Number of subjects: 50
Study 8245671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g and tinidatsole 500 mg
Number of subjects: 628
Study 8245671 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside (netilmycin 150 mg or tobramycin 80 mg) with tinidatsole
Number of subjects: 628
Study 3533818 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin treatment
Number of subjects: 22
Study 3533818 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 22
Study 31056923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM)
Number of subjects: 31
Study 27862873 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 948
Study 27862873 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 948
Study 26290082 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation group (119 patients)
Number of subjects: 810
Study 26290082 — intervention group
Group type: COMPARATOR
Intervention: No reoperation group (691 patients)
Number of subjects: 810
Study 23443753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 145
Study 23443753 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical comparator
Number of subjects: 145
Study 21067735 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Eye colonoscopy (TEC)
Number of subjects: 448
Study 21067735 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 448
Study 19210135 — intervention group
Group type: EXPERIMENTAL
Intervention: NER uncoated 2 x 500 mg
Number of subjects: 25
Study 19210135 — intervention group
Group type: EXPERIMENTAL
Intervention: NER coated 1 x 1000 mg
Number of subjects: 25
Study 19210135 — intervention group
Group type: EXPERIMENTAL
Intervention: NER coated 2 x 500 mg
Number of subjects: 25
Study 19210135 — intervention group
Group type: EXPERIMENTAL
Intervention: NER uncoated 1 x 1000 mg
Number of subjects: 25
Study 19210135 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 25
Study 16735333 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact at one month
Number of subjects: 605
Study 16735333 — intervention group
Group type: COMPARATOR
Intervention: Control (usual treatment)
Number of subjects: 605
Study 16735333 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact at three months
Number of subjects: 605
Study 15548759 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (alpha‐tocopherol 100 mg/day, beta‐carotene 6 mg/day, vitamin C 100 mg/day, selenium 50 microg/day)
Number of subjects: 106
Study 15548759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 11546715 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 microg x kg(‐1))
Number of subjects: 16
Study 11546715 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 9760346 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 6
Study 9760346 — intervention group
Group type: COMPARATOR
Intervention: Dextrose placebo
Number of subjects: 6
Study 8091168 — intervention group
Group type: EXPERIMENTAL
Intervention: OME/AMOX (oral OME 40 mg bid and AMOX solute 750 mg tid for 10 days)
Number of subjects: 52
Study 8091168 — intervention group
Group type: COMPARATOR
Intervention: OME (20 mg per day for 20 days)
Number of subjects: 52
Study 2968363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 36
Study 2968363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 36
Study 30013785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (375–3000 mg/day)
Number of subjects: 1359
Study 30013785 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (non-iron-based phosphate binders)
Number of subjects: 1359
Study 27129956 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session risk-reduction counseling intervention
Number of subjects: 0
Study 27129956 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard care (control)
Number of subjects: 0
Study 25789814 — intervention group
Group type: EXPERIMENTAL
Intervention: Full fan pattern at maximum smile
Number of subjects: 1392
Study 25789814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fan pattern
Number of subjects: 1392
Study 25789814 — intervention group
Group type: EXPERIMENTAL
Intervention: Full fan and lower fan patterns
Number of subjects: 1392
Study 25789814 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1392
Study 25789814 — intervention group
Group type: EXPERIMENTAL
Intervention: CFL pattern distribution
Number of subjects: 1392
Study 24101048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive temozolomide
Number of subjects: 182
Study 24101048 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (control)
Number of subjects: 182
Study 21816628 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral (GH) steroid injection
Number of subjects: 71
Study 21816628 — intervention group
Group type: COMPARATOR
Intervention: Subacromial (SA) steroid injection
Number of subjects: 71
Study 19386684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 200
Study 19386684 — intervention group
Group type: COMPARATOR
Intervention: Combined sedation (midazolam and hydrocodone)
Number of subjects: 200
Study 16690379 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude chiropractic adjustments
Number of subjects: 10
Study 16690379 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (control)
Number of subjects: 10
Study 15560690 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic enteric coated tablets for 3 months
Number of subjects: 100
Study 15560690 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 3 months
Number of subjects: 100
Study 11422249 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin‐clavulanate (13.3 mg/kg 3 times daily)
Number of subjects: 28
Study 11422249 — intervention group
Group type: EXPERIMENTAL
Intervention: cefuroxime axetil (15 mg/kg twice daily)
Number of subjects: 28
Study 9430448 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID, 5 mg, orally)
Number of subjects: 12
Study 9430448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP, 0.3 or 0.6 mM)
Number of subjects: 12
Study 9430448 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (10-8 M)
Number of subjects: 12
Study 9430448 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH with ID
Number of subjects: 12
Study 9430448 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 12
Study 9430448 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 12
Study 8018953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) treatment for less than 2 weeks
Number of subjects: 36
Study 8018953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) treatment for 2 weeks or more
Number of subjects: 36
Study 8018953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) treatment
Number of subjects: 36
Study 8018953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment
Number of subjects: 36
Study 8018953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment after 2 weeks
Number of subjects: 36
Study 3144446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride tablet programme (daily administration)
Number of subjects: 529
Study 3144446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride tablets)
Number of subjects: 529
Study 29233783 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute tDCS combined with 50mg/day of sertraline
Number of subjects: 69
Study 29233783 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute tDCS combined with 50mg/day of sertraline
Number of subjects: 69
Study 29233783 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 69
Study 26242834 — intervention group
Group type: EXPERIMENTAL
Intervention: External stent applied to SVGs
Number of subjects: 29
Study 26242834 — intervention group
Group type: COMPARATOR
Intervention: Nonstented SVGs (control)
Number of subjects: 29
Study 24202240 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus whole breast irradiation (WBI)
Number of subjects: 1428
Study 24202240 — intervention group
Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI) alone
Number of subjects: 1428
Study 16271726 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 428
Study 16271726 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg twice daily (BID)
Number of subjects: 428
Study 16271726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 12825868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg daily for 2 weeks
Number of subjects: 12
Study 12825868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10633478 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 ug/kg, i.m.) on night 2
Number of subjects: 12
Study 10633478 — intervention group
Group type: COMPARATOR
Intervention: Placebo on night 2
Number of subjects: 12
Study 10633478 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery night (night 3)
Number of subjects: 12
Study 7755525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 71
Study 7755525 — intervention group
Group type: COMPARATOR
Intervention: Exposure in vivo
Number of subjects: 71
Study 2076303 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-hour educational program including interactive discussion groups, influential peers, and self-formulated contracts.
Number of subjects: 0
Study 6247521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy alone
Number of subjects: 337
Study 6247521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy and radiotherapy (including prophylactic brain irradiation in four patients)
Number of subjects: 337
Study 6247521 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 337
Study 31950855 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 36
Study 31950855 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 36
Study 29084407 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime (9 a.m. to 5 p.m.)
Number of subjects: 24
Study 29084407 — intervention group
Group type: COMPARATOR
Intervention: Nighttime (9 p.m. to 5 a.m.)
Number of subjects: 24
Study 28356133 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage once daily for 6 weeks
Number of subjects: 0
Study 28356133 — intervention group
Group type: COMPARATOR
Intervention: No massage (control group)
Number of subjects: 0
Study 26240207 — intervention group
Group type: EXPERIMENTAL
Intervention: GARDASIL 9 (9‐valent human papillomavirus [9vHPV] vaccine) administered concomitantly with MCV4/Tdap
Number of subjects: 1241
Study 26240207 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV4/Tdap administered concomitantly with 9vHPV vaccine
Number of subjects: 1241
Study 26240207 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap administered concomitantly with 9vHPV vaccine
Number of subjects: 1241
Study 23207893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise session using a BOSU ball and a Swiss ball as unstable platforms (six 25-minute sessions).
Number of subjects: 37
Study 23207893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional proprioceptive training, only warm-up).
Number of subjects: 37
Study 21931078 — intervention group
Group type: EXPERIMENTAL
Intervention: Access arm with audible alerts for threshold crossings
Number of subjects: 335
Study 21931078 — intervention group
Group type: COMPARATOR
Intervention: Control arm without audible alerts
Number of subjects: 335
Study 21931078 — intervention group
Group type: EXPERIMENTAL
Intervention: Access arm
Number of subjects: 335
Study 21931078 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 335
Study 18241708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 60
Study 18241708 — intervention group
Group type: COMPARATOR
Intervention: Desflurane-based anesthesia
Number of subjects: 60
Study 15910632 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype of the MspI polymorphism of Apo AI
Number of subjects: 1224
Study 12637608 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX‐901 (450 mg)
Number of subjects: 84
Study 12637608 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX‐901 (300 mg)
Number of subjects: 84
Study 12637608 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX‐901 (150 mg)
Number of subjects: 84
Study 12637608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10680434 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole solution 800 mg day‐1
Number of subjects: 123
Study 10680434 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole solution 400 mg day‐1 (s/c1200)
Number of subjects: 123
Study 10680434 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole solution 400 mg day‐1 with loading dose of 800 mg day‐1 capsules for 7 days
Number of subjects: 123
Study 10680434 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole solution 400 mg day‐1
Number of subjects: 123
Study 10680434 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole capsules 400, 600 or 800 mg day‐1
Number of subjects: 123
Study 8619361 — intervention group
Group type: EXPERIMENTAL
Intervention: Iobitridol (250-300 mg)
Number of subjects: 139
Study 8619361 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (control for i.v. DSA)
Number of subjects: 139
Study 8619361 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (control for i.a. DSA)
Number of subjects: 139
Study 1768321 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent abortion history (short vs long)
Number of subjects: 165
Study 1768321 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age (over 30 years)
Number of subjects: 165
Study 1768321 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortion x years index
Number of subjects: 165
Study 1768321 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfertility problems
Number of subjects: 165
Study 7256696 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (0.6 g)
Number of subjects: 0
Study 7256696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (150 mg)
Number of subjects: 0
Study 7256696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31385041 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (20 mg, twice daily), started 24-36 hours after surgery and continued until discharge
Number of subjects: 121
Study 31385041 — intervention group
Group type: COMPARATOR
Intervention: IPC alone
Number of subjects: 121
Study 31084573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad group
Number of subjects: 48
Study 31084573 — intervention group
Group type: EXPERIMENTAL
Intervention: Large group
Number of subjects: 48
Study 31084573 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 48
Study 28596236 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic hypoglycemia (bolus insulin)
Number of subjects: 9
Study 28596236 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic euglycemia (bolus insulin and glucose infusion)
Number of subjects: 9
Study 28596236 — intervention group
Group type: COMPARATOR
Intervention: saline control
Number of subjects: 9
Study 26530312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP EN
Number of subjects: 100
Study 26530312 — intervention group
Group type: COMPARATOR
Intervention: Moderate-FODMAP EN
Number of subjects: 100
Study 26530312 — intervention group
Group type: COMPARATOR
Intervention: High-FODMAP EN
Number of subjects: 100
Study 26530312 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 100
Study 26530312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea improved group
Number of subjects: 100
Study 26530312 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent diarrhea/constipation improved group
Number of subjects: 100
Study 26530312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea-improved and recurrent diarrhea/constipation groups
Number of subjects: 100
Study 26530312 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation-improved group
Number of subjects: 100
Study 25651741 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise (cycloergometer)
Number of subjects: 87
Study 25651741 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercise (handgrip)
Number of subjects: 87
Study 21114411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral alprostadil 125 to 250 μg daily for 9 months
Number of subjects: 127
Study 21114411 — intervention group
Group type: COMPARATOR
Intervention: Oral sildenafil citrate 50 mg daily for 9 months
Number of subjects: 127
Study 19651563 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus acidophilus NCFM (N = 110)
Number of subjects: 326
Study 19651563 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus acidophilus NCFM + Bifidobacterium animalis subsp lactis Bi‐07 (N = 112)
Number of subjects: 326
Study 19651563 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (N = 104)
Number of subjects: 326
Study 17969892 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy-based complex systems partition method (EBCSPM)
Number of subjects: 403
Study 17969892 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 403
Study 15375810 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) - wearing a thick constraint mitten on the sound arm for as many as 6 hours a day
Number of subjects: 30
Study 15375810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11451210 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 10-80 mg
Number of subjects: 792
Study 11451210 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 2.5-40 mg
Number of subjects: 792
Study 9848557 — intervention group
Group type: EXPERIMENTAL
Intervention: Kessler repair
Number of subjects: 0
Study 9848557 — intervention group
Group type: EXPERIMENTAL
Intervention: Robertson repair
Number of subjects: 0
Study 9848557 — intervention group
Group type: COMPARATOR
Intervention: Locking Strickland repair
Number of subjects: 0
Study 9848557 — intervention group
Group type: COMPARATOR
Intervention: Modified Becker repair
Number of subjects: 0
Study 7532497 — intervention group
Group type: EXPERIMENTAL
Intervention: Remantadine (1.5 mg/kg body weight, 3 times a day for 3 days)
Number of subjects: 0
Study 7532497 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2527538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 23
Study 2527538 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 23
Study 2527538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1071671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (1-5-2-0 mg/kg)
Number of subjects: 20
Study 1071671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 20
Study 1071671 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of propranolol
Number of subjects: 20
Study 31121015 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (DOR) with lamivudine (3TC)/tenofovir disoproxil fumarate (TDF) or DOR (100 mg QD) with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC
Number of subjects: 747
Study 31121015 — intervention group
Group type: COMPARATOR
Intervention: Darunavir plus ritonavir (DRV+r) (800/100 mg QD) with FTC/TDF or ABC/3TC
Number of subjects: 747
Study 31121015 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) with FTC/TDF (600/200/300 mg QD)
Number of subjects: 747
Study 31121015 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (DOR)
Number of subjects: 747
Study 31121015 — intervention group
Group type: COMPARATOR
Intervention: Darunavir plus ritonavir (DRV+r)
Number of subjects: 747
Study 31121015 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 747
Study 28571997 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based patient-centered intervention delivered by a pharmacist, integrating brief negotiated interviewing and shared decision-making.
Number of subjects: 1400
Study 28571997 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1400
Study 25621378 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal eye movements
Number of subjects: 0
Study 25069344 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral ABS
Number of subjects: 55
Study 25069344 — intervention group
Group type: COMPARATOR
Intervention: Traditional intraoral ABS
Number of subjects: 55